Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $74.00

Xenon Pharmaceuticals (NASDAQ:XENE) had its price objective raised by HC Wainwright from $53.00 to $74.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ FY2027 earnings at ($6.05) EPS, FY2028 earnings at ($4.97) EPS, FY2029 earnings at ($3.06) EPS and FY2030 earnings at ($0.75) EPS.

XENE has been the topic of several other research reports. Needham & Company LLC lifted their target price on shares of Xenon Pharmaceuticals from $58.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday. Wolfe Research began coverage on shares of Xenon Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target on the stock. Morgan Stanley set a $97.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday. Wells Fargo & Company upped their price objective on shares of Xenon Pharmaceuticals from $48.00 to $49.00 and gave the company an “overweight” rating in a research note on Friday, February 27th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $71.94.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $57.90 on Tuesday. Xenon Pharmaceuticals has a 1 year low of $26.74 and a 1 year high of $63.95. The firm has a market capitalization of $4.82 billion, a PE ratio of -13.28 and a beta of 0.91. The business’s 50 day moving average price is $43.49 and its 200-day moving average price is $41.80.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the previous year, the business earned ($0.84) earnings per share. As a group, analysts expect that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Insider Activity at Xenon Pharmaceuticals

In related news, insider Christopher John Kenney sold 2,771 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $166,564.81. Following the completion of the sale, the insider directly owned 4,729 shares in the company, valued at approximately $284,260.19. This trade represents a 36.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $156,706.77. Following the transaction, the insider directly owned 4,893 shares in the company, valued at $294,118.23. This trade represents a 34.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 326,647 shares of company stock valued at $19,066,951. 4.07% of the stock is owned by company insiders.

Institutional Trading of Xenon Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC lifted its holdings in Xenon Pharmaceuticals by 0.5% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock valued at $243,124,000 after acquiring an additional 24,444 shares during the last quarter. Janus Henderson Group PLC increased its stake in Xenon Pharmaceuticals by 3.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company’s stock worth $183,110,000 after acquiring an additional 140,149 shares during the last quarter. Wellington Management Group LLP increased its stake in Xenon Pharmaceuticals by 66.0% during the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after acquiring an additional 1,435,096 shares during the last quarter. Braidwell LP raised its position in Xenon Pharmaceuticals by 33.0% in the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock valued at $112,837,000 after purchasing an additional 895,154 shares during the period. Finally, Capital International Investors lifted its stake in shares of Xenon Pharmaceuticals by 7.3% in the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after purchasing an additional 233,466 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Key Headlines Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Closed upsized offering — Xenon completed an upsized public offering that raised roughly $747.5M (including full exercise of the underwriters’ option), providing substantial cash to fund Phase‑3 activities, NDA planning and early commercial buildout, and materially lowering near‑term financing risk. GlobeNewswire: Closing of Offering
• Positive Sentiment: Clinical derisking — Xenon’s lead candidate azetukalner posted a positive Phase‑3 efficacy readout in focal‑onset seizures and management plans an NDA filing in 2026, which increases the program’s near‑term commercial value and supports upside case assumptions. Zacks: Azetukalner Study
• Positive Sentiment: Analyst support rising — Multiple brokerages raised price targets and maintained buy/overweight stances (examples: Deutsche Bank, HC Wainwright, Wells Fargo), which can attract momentum buyers and institutional interest. Deutsche Bank PT HC Wainwright Note
• Neutral Sentiment: Model updates — HC Wainwright adjusted multi‑year EPS forecasts (improving FY2028–FY2030 but nudging FY2027 worse), reflecting shifting timing/commercial assumptions; useful for modeling but still speculative. HC Wainwright EPS Revision
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (CEO sold ~270k shares; additional insiders sold smaller blocks), which reduces insider ownership and may concern some investors about timing/liquidity taking. SEC Filing: Insider Sales
• Negative Sentiment: Dilution risk — the large share issuance (and pre‑funded warrants / potential additional option shares) increases outstanding share count and can pressure near‑term per‑share metrics and valuation multiples despite the stronger cash position. GlobeNewswire: Closing of Offering

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.